AAAAAA

   
Results: 1-8 |
Results: 8
SDZ-PSC-833 - A NEW MULTIDRUG-RESISTANCE MODULATOR
Authors: COVELLI A
Citation: A. Covelli, SDZ-PSC-833 - A NEW MULTIDRUG-RESISTANCE MODULATOR, Tumori, 83(5), 1997, pp. 21-24
THE P-GLYCOPROTEIN INHIBITOR (PGP) PSC-833 INCREASES THE INTRACELLULAR CONCENTRATIONS OF DAUNORUBICIN (DNR) IN-VIVO IN PATIENTS WITH PGP POSITIVE AML
Authors: PAUL C TIDEFELT U GRUBER A LILIEMARK E SUNDMANENGBERG B JULIUSSON G STENKE L ELMHORNROSENBORG A MOLLGARD L LEHMANN S COVELLI A MALKHANDI J GUSTAVSSON B LILIEMARK J
Citation: C. Paul et al., THE P-GLYCOPROTEIN INHIBITOR (PGP) PSC-833 INCREASES THE INTRACELLULAR CONCENTRATIONS OF DAUNORUBICIN (DNR) IN-VIVO IN PATIENTS WITH PGP POSITIVE AML, Blood, 90(10), 1997, pp. 805-805
DOSE-FINDING STUDY OF PSC833, A NOVEL MDR REVERSING AGENT, WITH DAUNORUBICIN AND ARA-C IN UNTREATED ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)
Authors: SONNEVELD P LOWENBERG B VOSSEBELD P MALKHANDI J COVELLI A DEKKER AW OSSENKOPPELE G MILLIGAN D VERHOEF G FERRANT A YIN J GRATWOHL A KOVACSOVICS T BURNETT A
Citation: P. Sonneveld et al., DOSE-FINDING STUDY OF PSC833, A NOVEL MDR REVERSING AGENT, WITH DAUNORUBICIN AND ARA-C IN UNTREATED ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML), Blood, 90(10), 1997, pp. 2517-2517
A PHASE-I DOSE-FINDING STUDY OF PSC-833, A NOVEL MDR REVERSING AGENT,WITH MITOXANTRONE, ETOPOSIDE AND CYTARABINE (PSC-MEC) IN POOR-PROGNOSIS ACUTE-LEUKEMIA (AML)
Authors: VISANI G MILLIGAN D LEONI F CHANG J KELSEY S MARCUS R POWLES R SCHEY S COVELLI A
Citation: G. Visani et al., A PHASE-I DOSE-FINDING STUDY OF PSC-833, A NOVEL MDR REVERSING AGENT,WITH MITOXANTRONE, ETOPOSIDE AND CYTARABINE (PSC-MEC) IN POOR-PROGNOSIS ACUTE-LEUKEMIA (AML), Blood, 90(10), 1997, pp. 2518-2518
DESOGESTREL VERSUS GESTODENE IN ORAL-CONTRACEPTIVES - INFLUENCE ON THE CLINICAL AND HISTOMORPHOLOGICAL FEATURES OF BENIGN BREAST-DISEASE (VOL 55, PG 71, 1994)
Authors: DILIETO A DEROSA G ALBANO G PAGNANO AM CAMPANILE M TERRACCIANO L PONTILLO M CIMMINO E COVELLI A PALADINI A
Citation: A. Dilieto et al., DESOGESTREL VERSUS GESTODENE IN ORAL-CONTRACEPTIVES - INFLUENCE ON THE CLINICAL AND HISTOMORPHOLOGICAL FEATURES OF BENIGN BREAST-DISEASE (VOL 55, PG 71, 1994), European journal of obstetrics, gynecology, and reproductive biology, 58(1), 1995, pp. 101-101
CLIMACTERIC SYMPTOMS AND CONTROL OF THE CYCLE IN WOMEN AGED 35 YEARS OR OLDER TAKING AN ORAL-CONTRACEPTIVE WITH 0.150-MG DESOGESTREL AND 0.020-MG ETHINYLESTRADIOL
Authors: TROSSARELLI GF GENNARELLI G BENEDETTO C DEALOYSIO D MAULONI M FANIZZA G COVELLI A
Citation: Gf. Trossarelli et al., CLIMACTERIC SYMPTOMS AND CONTROL OF THE CYCLE IN WOMEN AGED 35 YEARS OR OLDER TAKING AN ORAL-CONTRACEPTIVE WITH 0.150-MG DESOGESTREL AND 0.020-MG ETHINYLESTRADIOL, Contraception, 51(1), 1995, pp. 13-18
DESOGESTREL VERSUS GESTODENE IN ORAL-CONTRACEPTIVES - INFLUENCE ON THE CLINICAL AND HISTOMORPHOLOGICAL FEATURES OF BENIGN BREAST DISEASE
Authors: DILIETO A DEROSA G ALBANO G PAGNANO AM CAMPANILE M TERRACCIANO L PONTILLO M CIMMINO E COVELLI A PALADINI A
Citation: A. Dilieto et al., DESOGESTREL VERSUS GESTODENE IN ORAL-CONTRACEPTIVES - INFLUENCE ON THE CLINICAL AND HISTOMORPHOLOGICAL FEATURES OF BENIGN BREAST DISEASE, European journal of obstetrics, gynecology, and reproductive biology, 55(1), 1994, pp. 73-85
EFFECTS OF AN ORAL-CONTRACEPTIVE COMBINATION CONTAINING 0.150 MG DESOGESTREL PLUS 0.020 MG ETHINYL ESTRADIOL ON HEALTHY PREMENOPAUSAL WOMEN
Authors: DEALOYSIO D MAULONI M RONCUZZI A ALTIERI P BOTTIGLIONI F TROSSARELLI GF FANIZZA G COVELLI A
Citation: D. Dealoysio et al., EFFECTS OF AN ORAL-CONTRACEPTIVE COMBINATION CONTAINING 0.150 MG DESOGESTREL PLUS 0.020 MG ETHINYL ESTRADIOL ON HEALTHY PREMENOPAUSAL WOMEN, Archives of gynecology and obstetrics, 253(1), 1993, pp. 15-19
Risultati: 1-8 |